A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2026-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize safety and to determine the Recommended Phase 2
Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation);
to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).